Single-ventricle palliation for high-risk neonates: examining the feasibility of an automated home monitoring system after stage I palliation

2012 ◽  
Vol 8 (2) ◽  
pp. 227-235 ◽  
Author(s):  
Russell Cross ◽  
Rachel Steury ◽  
Amy Randall ◽  
Mary Fuska ◽  
Craig Sable
2006 ◽  
Vol 131 (1) ◽  
pp. 163-171.e2 ◽  
Author(s):  
Emile A. Bacha ◽  
Suanne Daves ◽  
Joel Hardin ◽  
Ra-id Abdulla ◽  
Jennifer Anderson ◽  
...  

2019 ◽  
Vol 10 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Valdano Manuel ◽  
Humberto Morais ◽  
Aida L. R. Turquetto ◽  
Gade Miguel ◽  
Leonardo A. Miana ◽  
...  

Introduction: Single ventricle physiology management is challenging, especially in low-income countries. Objective: To report the palliation outcomes of single ventricle patients in a developing African country. Methods: We retrospectively studied 83 consecutive patients subjected to single ventricle palliation in a single center between March 2011 and December 2017. Preoperative data, surgical factors, postoperative results, and survival outcomes were analyzed. The patients were divided by palliation stage: I (pulmonary artery banding [PAB] or Blalock–Taussig shunt [BTS]), II (Glenn procedure), or III (Fontan procedure). Results: Of the 83 patients who underwent palliation (stages I-III), 38 deaths were observed (31 after stage I, six after stage II, and one after stage III) for an overall mortality of 45.7%. The main causes of operative mortality were multiple organ dysfunction due to sepsis, shunt occlusion, and cardiogenic shock. Twenty-eight survivors were lost to follow-up (22 after stage I, six after stage II). Thirteen stage II survivors are still waiting for stage III. The mean follow-up was 366 ± 369 days. Five-year survival was 28.4 % for PAB and 30.1% for BTS, while that for stage II and III was 49.8% and 57.1%, respectively. Age (hazard ratio, 0.61; 95% confidence interval: 0.47-0.7; P = .000) and weight at surgery (hazard ratio, 0.45; 95% confidence interval: 0.31-0.64; P = .002) impacted survival. Conclusion: A high-mortality rate was observed in this initial experience, mainly in stage I patients. A large number of patients were lost to follow-up. A task force to improve outcomes is urgently required.


Author(s):  
Sheba John ◽  
Laura Schoeneberg ◽  
Christopher E. Greenleaf ◽  
Jorge D. Salazar ◽  
Dilachew A. Adebo

2017 ◽  
Vol 38 (1) ◽  
pp. 206-206
Author(s):  
Daniel Alexander Castellanos ◽  
Cynthia Herrington ◽  
Stacey Adler ◽  
Karen Haas ◽  
S. Ram Kumar ◽  
...  

2014 ◽  
Vol 25 (3) ◽  
pp. 539-543 ◽  
Author(s):  
Yinn K. Ooi ◽  
Pranava Sinha ◽  
Marcin Gierdalski ◽  
Ashraf Harahsheh

AbstractBackground: Of the children with Down syndrome 40–50% have cardiac defects and the majority of these cardiac defects are amenable to biventricular repair. The outcome of single ventricle palliation is improving; nonetheless, there are limited data on Down syndrome patients with associated high-risk factors undergoing single ventricle palliation. Our aim was to study the outcomes of children with Down syndrome and high-risk factors on the single ventricle palliation pathway. Methods: A retrospective study on all patients with Down syndrome on the single ventricle palliation pathway from 2005 until 2011 was conducted. Operative, clinical, echocardiographic, haemodynamic data, and follow-up data were reviewed. Results: A total of 310 patients underwent at least one single ventricle surgical intervention. Of those, eight patients had Down syndrome, five of which had associated risk factors – low birth weight, high pulmonary vascular resistance, pulmonary vein stenosis, significant atrioventricular valve regurgitation, and extracardiac anomalies. Mortality in the high-risk group was 80% (4/5), compared with 33% (1/3) in the non-high-risk patients. Overall, after a median follow-up period of 138 days (8–576 days), only 37.5% (3/8) of patients were alive. Conclusion: Despite many improvements in the care of single ventricle patients, the fate of those with Down syndrome and associated high-risk factors remains poor. Further multicentre longer-term studies are needed to validate and quantify the cumulative effects of negative prognostic factors in this complex group of patients.


2016 ◽  
Vol 37 (8) ◽  
pp. 1575-1580 ◽  
Author(s):  
Daniel Alexander Castellanos ◽  
Cynthia Herrington ◽  
Stacey Adler ◽  
Karen Haas ◽  
S. Ram Kumar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document